Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
about
Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoringPharmacokinetic drug interaction profiles of proton pump inhibitors: an updateDiclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug InteractionOmeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cellsProton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)Evaluation of memory enhancing clinically available standardized extract of Bacopa monniera on P-glycoprotein and cytochrome P450 3A in Sprague-Dawley ratsSynergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult WormsClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction.Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers.Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.Erlotinib and pantoprazole: a relevant interaction or not?Drug-drug interaction between clopidogrel and the proton pump inhibitors.Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patientsThe reversal of multidrug resistance: an update.Acetazolamide may provoke cyclosporine toxicity-a case report.ABC of oral bioavailability: transporters as gatekeepers in the gut.Effect of bacterial and host factors on Helicobacter pylori eradication therapyDifferent inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesEffects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy.Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone.Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteersTreatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo.Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors.Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta-analysis.In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.Loperamide-Related Deaths in North Carolina."Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic reviewRenal Drug Transporters and Drug Interactions.Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.Acute colchicine intoxication during clarithromycin administration.
P2860
Q24799859-E23D0FB4-C831-43A2-B0A9-5F6D8419570BQ27022254-0A9C677D-6217-4C46-AD67-91F5CFB5B6E2Q28078254-2C925EAB-DB9A-49E4-9583-E22BD0713380Q28478262-D714D919-E8F1-44E2-BBC5-34AF1BCA8B3AQ28479037-A7D770B2-2B07-420C-88B8-90AE2C0DC759Q28535796-3DA652C7-D351-412A-AB6C-23F12D2C71DFQ28548401-0650D877-E4D4-4AD2-9C39-FA00344640C0Q30234940-1382DDFC-FC93-4F6F-AE06-F48CAFDD31CDQ33148996-723F18C1-E726-45D0-BF3D-E20F48FFDB42Q33667262-01E15BB8-6297-4D5C-B9DA-7DE60160CD1DQ33908105-EFF37000-DD7C-4D94-B7AE-E95BC2DB251BQ34290110-2720B595-8370-4E38-8B07-E76EAD770F66Q34457467-8C6187B0-F556-4F0E-8F42-A7BFD76A0A4BQ34983154-C654522A-36E5-474A-B1D6-5189C9CDB3E0Q34994901-71F93C9C-9DF1-478E-A475-6BD3D1D28511Q35010908-F4942CA1-41D9-42ED-8FE6-FC29DF747AD4Q35118813-BECBF12B-E619-4671-B435-DD7250BA1EFCQ35573807-FB641C05-EFED-4C18-B0AC-BF10D9D8ACCBQ35591517-83C5BA41-F457-4C42-9C33-098C8A40706DQ35738262-0C7953CE-C4BB-421C-A012-2D1AA08B6834Q35826075-69D99E30-0DAA-4E4B-AE2A-7F84394DD5C8Q35826832-32CFB2AC-E19E-40E1-8A07-A8A56855BB53Q36018618-F37AF510-216E-4D93-8A78-2F31ABB60B2BQ36856634-B28CF4C9-8940-46DE-AC61-5C7F1070B5EDQ36900535-022F648B-66A4-4CDE-8705-D2E7DD6053B1Q36922216-25B60D40-3816-4066-8BE4-8E9A5141BC53Q36979297-D64A770C-B672-48FF-A88C-D16FF76219D9Q37146401-BE9E291D-E8CE-4CE1-BB2D-BF5696A6C07EQ37173189-C42D5CCC-DFE5-4977-8E81-748C14683A13Q37693951-680C2973-830B-4734-9D87-8E83A28CCFC7Q37979853-07CD2059-18EB-4214-994A-635B7E824DB7Q38150978-18997249-74E7-45D2-886A-89053BE0D9C0Q38738159-4F3BBC0D-07F5-4A9D-BC88-E813CD06498EQ38833665-F67AA4A0-DE14-48F6-BC58-6353E1592355Q38913158-A298BAB1-1273-412B-BAE1-0CCE1519447AQ38970000-8E467A48-3114-4A10-BE46-DCCB649812B6Q39013332-82FD099C-EE57-4BC2-A1A1-D7763EBF8E0CQ39140289-32B9CBB7-197A-4DD4-B2A6-7EB2BBE2C06CQ40471212-53B947A6-3291-4F82-AC72-26C206CD6269Q40523203-C437B164-9A9B-43BD-8248-383E1A66A7B2
P2860
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@ast
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@en
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@nl
type
label
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@ast
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@en
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@nl
prefLabel
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@ast
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@en
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@nl
P2093
P1476
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
@en
P2093
C Pauli-Magnus
S Rekersbrink
P2888
P304
P356
10.1007/S00210-001-0489-7
P577
2001-12-01T00:00:00Z
P6179
1034412986